Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once-Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta-Analysis., PMID:40509887
Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?, PMID:40497353
Multicenter, Retrospective, observational study to evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with Type-2 diabetes (T2D)., PMID:40469149
Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec., PMID:40465144
Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England., PMID:40441739
Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial., PMID:40318682
Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE Study., PMID:40309264
Insulin degludec/insulin aspart (IDegAsp) treatment on glycemic control and weight in patients with insulin experienced uncontrolled type 2 diabetes mellitus: A retrospective observational study., PMID:40258224
Exploring the Impact of Diabetes on Kidney Transplant: Patient Outcomes and Management Strategies., PMID:40255815
Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study., PMID:40236299
Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies., PMID:40176458
Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine., PMID:40162894
Once-weekly Basal Insulin Fc versus daily insulin degludec for glycemic control in diabetes: a systematic review, meta-analysis, and meta-regression., PMID:40123989
A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes., PMID:40098469
Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes: The INHALE-3 Extension Study., PMID:40098468
Premixed insulin: Advantages, disadvantages, and future., PMID:40093285
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme., PMID:40083081
An overview of insulin therapy for the non-specialist., PMID:40035222
Once-Weekly Insulin Icodec Versus Once-Daily Insulin Degludec in Insulin-Naive Chinese Participants with Type 2 Diabetes: A Post Hoc Analysis of ONWARDS 3., PMID:40016570
In-Hospital Management of Hyperglycemia: The Role of Insulin Degludec., PMID:40014293
No evidence of increased hypoglycaemia attributed to physical activity with once-weekly insulin icodec versus once-daily basal insulin degludec in type 1 diabetes: A post hoc analysis of ONWARDS 6., PMID:39972508
Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4, a novel once-weekly basal insulin, in healthy participants: A randomized trial., PMID:39935080
Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteers., PMID:39930729
Pharmacokinetic and Pharmacodynamic Properties of Once-Weekly Insulin Efsitora Alfa in Japanese Patients with Type 2 Diabetes., PMID:39928225
How to improve the quality of euglycemic glucose clamp tests in long-acting insulin studies., PMID:39893469
Slow progression of type 1 diabetes associated with pembrolizumab and lenvatinib combination therapy in a patient with probable slowly progressive type 1 diabetes mellitus and endometrial cancer., PMID:39877434
Pharmacotherapy of type 1 diabetes - part 1: yesterday., PMID:39875200
Insulin degludec 100 U/mL for treatment of spontaneous diabetes mellitus in dogs., PMID:39844001
Distribution-based sub-population selection (DSPS): A method for in-silico reproduction of clinical trials outcomes., PMID:39837001
Use of Degludec in Youth With Type 1 Diabetes and Recurrent Diabetic Ketoacidosis., PMID:39829694
Efficacy, safety and treatment satisfaction of transition to a regimen of insulin degludec/aspart: A pilot study., PMID:39817213
Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia., PMID:39802245
Severe palmoplantar keratoderma: a cutaneous complication from sub-optimally controlled type 2 diabetes., PMID:39786791
In T1D, weekly efsitora was noninferior to daily degludec for reducing HbA1c but increased severe hypoglycemia at 26 wk., PMID:39761586
In insulin-naive T2D, weekly efsitora was noninferior to daily degludec for reducing HbA1c at 52 wk., PMID:39761579
Newer Insulin Preparations and Insulin Analogs., PMID:39734941
Insulin Degludec in Critically Ill Patients With Type 2 Diabetes Mellitus: A Prospective Interventional Study., PMID:39725356
Optimal Use of Once-Weekly Basal Insulin Efsitora Alfa in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis., PMID:39710291
Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China., PMID:39703112
Effect of dapagliflozin on the serum metabolome in patients with type 2 diabetes mellitus., PMID:39697865
Efficacy and safety of switching to insulin glargine 300 U/mL in people with type 2 diabetes uncontrolled on basal insulin in China: A post hoc subpopulation analysis of the INITIATION study., PMID:39691971
A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes., PMID:39641970
Basal insulin analogues in type 1 diabetes - Does one size fit all? Lessons from the HypoDeg trial based on single-patient outcomes., PMID:39624290
Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults With Type 2 Diabetes in the Philippines: Results from a Prospective, Non-interventional, Real-World Study., PMID:39620193
Effects of insulin glargine U300 versus insulin degludec U100 on glycemic variability, hypoglycemia, and diet evaluated by continuous glucose monitoring in type 1 diabetes: a retrospective cross-sectional study., PMID:39588847
Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity., PMID:39566870
Economic Evaluation of Once-Weekly Insulin Icodec from Italian NHS Perspective., PMID:39525695
Survey of fear and compliance of Insulin Degludec and Insulin Aspart injection in type 2 diabetes mellitus patients and analysis of influencing factors., PMID:39533598
De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D)., PMID:39532398
Initiation or switch to insulin degludec/insulin aspart in adults with type 2 diabetes in India: Results from a prospective, non-interventional, real-world study., PMID:39464932
For research use only. Not for human or drug use.
